GlassScriptPhysician profile
Danielle Ratter
NPI 1073271961
$755.06
in general payments reported to CMS, 2019-2025
12 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $131 · 2023: $245 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.77 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $198.08 | 2022-2023 | |
| Genzyme Corporation | $127.53 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Jazz Pharmaceuticals INC. | $90.00 | 2025 | |
| Glaxosmithkline, LLC. | $63.63 | 2023-2025 | Nucala |
| Verona Pharma, INC. | $55.55 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $30.49 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.98 | 2025 | Jascayd |
| Medtronic, INC. | $17.66 | 2022 | |
| Harmony Biosciences LLC | $17.61 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $17.37 | 2025 | Tezspire |
| United Therapeutics Corporation | $15.17 | 2025 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Ratter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.